1. 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials. (April 2018) Authors: Lerebours, F.; Pulido, M.; Fourme, E.; Debled, M.; Becette, V.; Bonnefoi, H.; Rivera, S.; Mac Grogan, G.; Mouret-Reynier, M.A.; Tunon de Lara, C.; Pierga, J.Y.; Breton-Callu, C.; Venat-Bouvet, L.; Mathoulin-Pelissier, S.; Kerbrat, P.; Dalenc, F.; Sigal, B.; Bachelot, T.; Lemonnier, J.; Lerebours, Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗